Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)

Summary

The purpose of this study is to evaluate the efficacy and safety of the subcutaneous administration for 45 days of Bemiparin (3,500 UI/day) in cancer patients with a CVC, to prevent CVC-related deep venous thrombosis (CVC-DVT)

Conditions

• Cancer
• Thrombosis

Interventions

DRUG

Bemiparin

DRUG

Placebo

Sponsors & Collaborators

• Laboratorio farmacéutico ROVI

  collaborator UNKNOWN

• Clinica Universidad de Navarra, Universidad de Navarra

  lead OTHER

Principal Investigators

• Eduardo Rocha, MD · Clinica Universitaria de Navarra

• Ramon Lecumberri, MD · Clinica Universitaria de Navarra

• Vicente Vicente, MD · Hospital Morales Meseguer

• Pascual Marco, MD · Hospital General Universitario de Alicante

• José Mateo, MD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

• Albert Font, MD · Germans Trias i Pujol Hospital

• Carmen Arratibel, MD · Complejo Hospitalario de Donostia

• Francisco J. Capote, MD · Hospital Universitario Puerta del Mar

• Miguel Angel De gregorio Ariza, MD · Hospital Clinico Universitario Lozano Blesa-Zaragoza

• Isabel Picón Roig, MD · Instituto Valenciano de Oncología

• Ricardo González Del Val Subirats, MD · Hospital General Universitario Gregorio Marañón

• Carlos Bosh Roig, MD · Hospital Universitario Doctor Peset

• Pedro Pérez-Segura, MD · Hospital Clínico San Carlos-Madrid.

• Vicente Alberola, MD · Hospital Arnau de Vilanova de Valencia

• César Rodríguez Sánchez, MD · Hospital Clínico de Salamanca

• Ignacio Alberca Silva, MD · Hospital Clínico de Salamanca

• Javier García Frade, MD · Hospital del Rio Hortega

• Carmen Sedano, MD · Hospital Marqués de Valdecilla

• Natividad Gómez, MD · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

• Amalia Velasco, MD · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

• Carmen Rodríguez Pinto, MD · Hospital Universitario Central de Asturias

• Mihai Ciochinaru, MD · Cenral Emergency Clinical Military H.

• Cornelia Toganel, MD · District Emergency Clinical Hospital

• Csaba Bela Szekely, MD · Arad District Hospital

• Mihaela Danciulescu, MD · Filantropia District Hospital

• Constantin Volovat, MD · Oncology Medical Center Iasi

• Mircea Cazacu, Prof. · University "CF" Clinical Hospital

• Eliade Ciuleanu, MD · Oncology Institute Cuj-Napoca

• Florin Bacanu, md · Sf Maria Clinical Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-07-31

Primary Completion

2009-02-28

Completion

2010-12-31

Countries

• Romania
• Spain

Study Locations